PURPOSE: Second hand smoke (SHS) exposure is associated with higher risk of lung cancer. However, the role of SHS in lung cancer survival is not clear. EXPERIMENTAL DESIGN: We examined the association between self-reported SHS exposure before diagnosis and overall survival and recurrence-free survival in 393 early-stage non-small-cell lung cancer patients. SHS exposure was analyzed by both duration and location of exposure using log-rank test and Cox proportional hazard models, adjusting for covariates including pack-years of smoking. RESULTS: The median follow-up time was 66 months (range, 0.2-140 months). There were 135 recurrences and 213 deaths. The 5-year overall survival rates were 71% [95% confidence interval (95% CI), 62-81%], 61% (51-72%), 49% (38-60%), and 47% (37-58%), respectively, for patients with the lowest to highest quartile of SHS exposure durations (P < 0.001, log-rank test), with the adjusted hazard ratio (AHR) of 1.57 (95% CI, 1.02-2.41) for the highest versus lowest quartile of SHS exposure durations (P(trend) = 0.04). For different SHS exposure locations, a stronger association was found for SHS exposure at work (AHR of the highest versus lowest quartile, 1.71; 95% CI, 1.12-2.61; P(trend) = 0.03) than for exposure at home (AHR, 1.26; 95% CI, 0.86-1.86; P(trend) = 0.20) or leisure places (AHR, 1.28; 95% CI, 0.83-1.95; P(trend) = 0.16). Similar associations were observed when SHS exposure durations were dichotomized into two or three groups and between SHS exposure and recurrence-free survival. CONCLUSIONS: SHS exposure is associated with worse survival in early-stage non-small-cell lung cancer patients, especially for SHS exposure at the work.
PURPOSE: Second hand smoke (SHS) exposure is associated with higher risk of lung cancer. However, the role of SHS in lung cancer survival is not clear. EXPERIMENTAL DESIGN: We examined the association between self-reported SHS exposure before diagnosis and overall survival and recurrence-free survival in 393 early-stage non-small-cell lung cancerpatients. SHS exposure was analyzed by both duration and location of exposure using log-rank test and Cox proportional hazard models, adjusting for covariates including pack-years of smoking. RESULTS: The median follow-up time was 66 months (range, 0.2-140 months). There were 135 recurrences and 213 deaths. The 5-year overall survival rates were 71% [95% confidence interval (95% CI), 62-81%], 61% (51-72%), 49% (38-60%), and 47% (37-58%), respectively, for patients with the lowest to highest quartile of SHS exposure durations (P < 0.001, log-rank test), with the adjusted hazard ratio (AHR) of 1.57 (95% CI, 1.02-2.41) for the highest versus lowest quartile of SHS exposure durations (P(trend) = 0.04). For different SHS exposure locations, a stronger association was found for SHS exposure at work (AHR of the highest versus lowest quartile, 1.71; 95% CI, 1.12-2.61; P(trend) = 0.03) than for exposure at home (AHR, 1.26; 95% CI, 0.86-1.86; P(trend) = 0.20) or leisure places (AHR, 1.28; 95% CI, 0.83-1.95; P(trend) = 0.16). Similar associations were observed when SHS exposure durations were dichotomized into two or three groups and between SHS exposure and recurrence-free survival. CONCLUSIONS: SHS exposure is associated with worse survival in early-stage non-small-cell lung cancerpatients, especially for SHS exposure at the work.
Authors: V Kašuba; R Rozgaj; M Milić; D Zelježić; N Kopjar; A Pizent; Z Kljaković-Gašpić; A Jazbec Journal: Int Arch Occup Environ Health Date: 2011-12-09 Impact factor: 3.015
Authors: Taghrid Asfar; Kristopher L Arheart; Tulay Koru-Sengul; Margaret M Byrne; Noella A Dietz; Charles Jeng Chen; David J Lee Journal: J Cancer Surviv Date: 2017-02-21 Impact factor: 4.442
Authors: Yen-Tsung Huang; Xihong Lin; Yan Liu; Lucian R Chirieac; Ray McGovern; John Wain; Rebecca Heist; Vidar Skaug; Shanbeh Zienolddiny; Aage Haugen; Li Su; Edward A Fox; Kwok-Kin Wong; David C Christiani Journal: Proc Natl Acad Sci U S A Date: 2011-09-12 Impact factor: 11.205
Authors: Oladimeji Akinboro; Odunayo Olorunfemi; Prasanta Basak; Elizabeth Phillips; Daniel Pomerantz; Bernard Bernhardt; Rasim Gucalp; Stephen Jesmajian; Jamie S Ostroff Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-06-22 Impact factor: 4.254
Authors: Mary E Cooley; Linda Sarna; Jenny Kotlerman; Jeanne M Lukanich; Michael Jaklitsch; Sarah B Green; Raphael Bueno Journal: Lung Cancer Date: 2009-03-24 Impact factor: 5.705
Authors: Meredith Elana Giuliani; Geoffrey Liu; Wei Xu; Mihaela Dirlea; Peter Selby; Janet Papadakos; Nazek Abdelmutti; Dongyang Yang; Lawson Eng; David Paul Goldstein; Jennifer Michelle Jones Journal: J Med Internet Res Date: 2019-04-09 Impact factor: 5.428